Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton´s Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS
- 13.05.2019, 13:25
- Kategoria: Biznes i finanse
- Źródło: PR Newswire